** Shares of drug developer Quince Therapeutics QNCX.O down shares down 91.7% at 24 cents in afternoon trading

** Company says its experimental drug did not meet primary and secondary goal of a late-stage study in patients with rare, inherited neurodegenerative disorder

** Ataxia‑telangiectasia is a rare, inherited neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene which appears in early childhood and leads to problems with movement, weakening of the immune system, and frequent infections

** Patients receiving co's drug, eDSP, did not see clinically meaningful improvement in symptoms compared to those on placebo after six months of treatment in late-stage study

** eDSP was generally well tolerated, with no clinically meaningful safety concerns identified - ONCX

** Co says among the side effects that did occur, the two most frequent were itching and fever

** Stock has been down 18.1% in 2025

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))